iati israel’s life science annual industry report

2021IATI Israel’s Life ScienceAnnual Industry Report

In partnership with

Connecting Israel’s Tech Ecosystem

With the support of

In cooperation with

IATI Members and Senior OfficialsBring Their Personal Take

on the Israeli Life Science Industry

Testimonials

Connecting Israel’s tech ecosystem Connecting Israel’s tech ecosystem

IATI Promotes and Supports the Entire High Tech and Life Science industries

with Hundreds of Paying Members

To learn more about joining IATI:

Herzliya Pituach, IsraelT: +972 73713 6313 / [email protected] / www.iati.co.il

Connecting Israel’s tech ecosystem

Academia H

ospi

tals

Tech TransferO�ces

Multinational

Companies

R&D CentersVentureCapital funds

Entrepreneurs

Incubators

Mat

ure

Israe

li

Com

pani

es

Economic

Development

O�ces

Start-ups

Priva

te

inves

tors

Stock Exchanges

Service

Providers

Innovation

Centers

Mun

icip

aliti

es

Connecting Israel’s tech ecosystem Connecting Israel’s tech ecosystem3

Executive summary

IATI Israel’s Life Science Annual Industry Report: Israel’s Life Sciences Industry, provides the broadest, deepest view of this thriving industry. The continuity, the annual comparison and the long-term view, all make the Report the most comprehensive take on the Israeli Life Science Industry. As the Israel’s Umbrella Organization of the High-Tech & Life Science industries, IATI continuously acts to connect and promote the country’s massive resources of academic and technological prowess towards creating a fertile ecosystem which will nourish growth in the coming years as well.

The Israeli life science industry kept growing in 2020 despite the COVID-19 pandemic. Continuance increase in the number of companies, stable maturity levels and innovation in new and developing sectors, all contribute to the industry's success and significant role in the Israeli economy. Similar to prior years however, with less than 50% of companies located off the central area of Israel (known here as the Periphery), this success is not yet equally spread. Not enough actions are taken to encourage entrepreneurs bring their companies to these areas, and we believe there is more that should be done.

After putting a spotlight on the industry's rising sub-sectors in our prior report, we focus this time on some new promising sub-sectors and following up on those we have identified in the past. This is in addition to the traditional sub-sectors discussed in our prior reports. The spotlight is put on those sectors not only because they are fast populated by new companies and attract more investments, but mainly as being leaders in innovation and multidisciplinary abilities, demonstrating the industry's ability to take advantage of the excellence in academic research, deep government support and the innovative ecosystem in Israel.

The healthtech industry has been experiencing dramatic changes due to the COVID-19 pandemic. From unique collaborations with players coming outside of the life sciences industry through fast paced adoption of digital health and remote health solutions, the pandemic had a huge impact on the industry. This also led to a record year when it comes to funding, with the first quarter of 2021 continuing the trend.

The healthcare landscape is continuing to shift towards a more integrated ecosystem, converging biopharma, medtech, digital health and healthcare into a single bio-convergent industry. This emerging bio-convergent healthtech space holds great potential to make a transformative impact on health and healthcare practices. When it comes to holding a leading position in this emerging bio-convergent field, Israel has substantial strengths and capabilities.


A broader discussion on Israel's value proposition in the bio-convergent sphere can be found in the "Bio-Convergence Revolution" chapter of this report.

The healthcare system is confronting skyrocketing costs, while the biopharma industry is coming up against aggressive pricing pressures. In an effort to meet these challenges, the healthtech industry is seeking new innovation growth engines. Israeli life science companies can play, and in many ways already are playing, a leading role in facing the coming challenges. Fostering digital health innovation to address actual needs and not perceived ones, for example, can lead to significant improvements in integrating technological solutions, even from sources outside of traditional healthcare. We invite you to read insights from the field in the "How Can the Israeli Health-Tech Industry Reduce the Cost Burden" chapter and throughout the report.

I would like to warmly thank the Israeli Innovation Authority for supporting this Report and for partnering with us on promoting the industry throughout the year; Omer Gavish, Partner, Pharmaceuticals & Life Sciences Leader at PwC Israel, for all the support in preparing this Report; Dr. Yair Schindel, Co-Founder & Managing Partner and the team of aMoon Fund; Oded Har-Even, Co Managing Partner, Sullivan & Worcester Tel-Aviv; and Assaf Harel, Partner, Gornitzky & Co.

Here’s to another year of Israeli biomedical pride!

Karin Mayer Rubinstein

CEO & President

IATI

All rights reserved for IATI - Israel Advanced Technology Industries (R.A)© ("IATI") . No part of this publication may be reproduced, copied, photocopied, stored in retrieval system, transmitted by electronic, mechanical, photocopying or recording means in any form in whole or in part - without the prior written permission of IATI.


Amir London - CEO, Kamada

"The main strengths of the Israeli life science industry are the strong scientific foundation in Israel, the close ties between the academia, the medical community, and leading entrepreneurs, and the innovative “out of the box” startup mindset of so many Israelis."

Dr. Ami Appelbaum - Chairman, Israel Innovation Authority and Chief Scientist, Ministry of Economy and Industry

“Israel is recognized as an innovation hub. This is due mainly to innovations made in the field of Information and Communication Technologies ‚ICTƒ. Israel boasts the highest concentration of PHDs per capita and has world leading research institutes. New and advanced developments of artificial intelligence and big data provide Israel a unique foothold for the Israeli life science industry. Creating breakthrough solutions and products to serve as a strong growth engine for the Israeli industry and economy as well as transform the entire life science industry both on a local and global perspective.”

Dr. Anat Cohen Dayag - President & CEO, Compugen

“Scientific excellence and an entrepreneurial spirit are two of the major strengths of the Israeli life sciences industry, and what make Israel an attractive innovation center. With this infrastructure we now need to build life science product development capabilities to facilitate the transition from early-stage product opportunities to a more advanced product development industry, leading toward a sustainable biotech model.”

Asaf Shiloni - CEO , Kadimastem

"The Israeli Biotech strength stems from the entrepreneurs, a combination of intelligence, innovation, creativity, and independence, as well as the scientist’s determination to press on in the face of daunting opposition. Moving back to Israel, I can attest that one of the key factors to success lies in the fact that Israeli employees think out of the box, when presented with a job description, they look beyond the framework of what it is supposed to be and go above and beyond to take the position to the next level, embracing responsibility and risk-taking."

Avi Wener - Country Director, Thermo Fisher Scientific

“The success of Israel’s life science industry can be attributed to the caliber of its scientists and the remarkable collaboration between its academic institutions, hospitals, HMOs and government bodies. The entrepreneurial spirit for which Israel is so famous permeates its life sciences community, ensuring Israel’s leadership in this field for many years to come.”

IATI Members and Senior Officials Bring Their Personal Take on the Israeli Life Science Industry


Ayelet Altman - CEO, NeuroDerm

"Israel is fertile ground for new business models in life-science, that brings together the strengths of Pharma and MedTech under one roof, while putting the patient and healthcare providers in the center. In the post-COVID era, Pharma/ MedTech convergence models are seen as the future, and Israel is playing an active role in the formation of this change. The Israeli Life-Science industry was founded utilizing Israel's entrepreneurial spirit, agility and adaptability, combined with an ability to face multiple challenges simultaneously and rapidly adapt and respond to them. These same capabilities allows for successful integration between two different worlds – Pharma and MedTech – aspired to make a meaningful difference in patients’ lives and drive future healthcare connectivity."

Ben Enosh - President & Chairman, Antidote Health

"The potential benefits of artificial intelegence are huge, leading to innovations that have been considered science fiction until recently. Good AI requires high quality data which the health system in Israel has been digitizing and collecting for years.

Bundling this data with deep AI knowledge positions Israel, to become a leading force in health innovations, for decades to come."

Claudio Yarza - Partner, Assurance Leader, PwC Israel

“The strength of the life science industry in Israel lies in its PEOPLE, who bring a unique combination of scientific knowledge, experience and a fresh interdisciplinary approach to unsolved needs, together with the strong determination and the pinch of chutzpah required to build successful startups under constant budget constraints."

Daphna Murvitz - Co-Founder and CEO, 8400 The Health Network

"The strength of the HealthTech industry in Israel lies not only in the high quality of translational research and inventiveness that fuels innovative cures, but also in the collaborative nature of our HealthTech ecosystem, which unlocks industry opportunities and healthcare solutions. The 8400 Health Network amplifies this unique talent, digital health data and cross-silo spillover through the cross-disciplinary Network."

Prof. David Sidransky, MD - Co-Founder and Managing Partner of Israel Biotech Fund

"In recent years, we have witnessed clear signs of maturity in the growing Israeli Biotech ecosystem. The increase in private and public investment rounds allows Biotech companies to hire experienced managers and to better execute on the drug development process and strategy. We foresee a great future for this industry and are proud to take part in this process."

David Abraham - Managing Director, Robert Bosch Technologies Israel Ltd.

"The unique coupling of prominent academic strength – 5 of Israel’s 12 Nobel prizes are in Chemistry, related to Life Sciences (Technion & WIS) – and an innovation-driven culture. Amalgamated with a seasoned pharmaceutical industry, intensive operational experience of hospitals and HMOs, and with the entrepreneurial skills of the technology ecosystem, it leads to a vibrant and well-diversified cluster, on a global scale, that is focused on Pharma, Medical Devices, Biotech and Digital Health. In numbers the life science sector is responsible for 15% of export, 20% of VC capital, 30% of IIA budget, and 50% of Academic IP. While we engineers like to think of Israel as an ICT country, it is no less a (Pro) Life Science country".


Dan Shwarzman - CEO, MindUP

"We see some exciting directions in healthcare innovation in Israel like bioconvergence, taking care from the hospital to home, and data-driven precision therapies. We are actively investing in these areas that can change the future of healthcare."

Dedi Gilad - CEO, Co-Founder, Tyto Care

“The strength of the life science industry in Israel lies in the powerful combination of innovation, breaking boundaries in several life science dimensions; Strong R&D capabilities; Educated and skilled workforce, with the highest percentage of engineers and scientists per capita in the world; and a mindset of flexibility & adaptability, which enables learning quickly, challenging, and improving existing regulatory and business models.”

Prof. Dror Harats - CEO, VBL Therapeutics

“Our biotech ecosystem is mirroring Israel’s unique mentality – highly educated people looking for innovative ideas by thinking outside the box, who are able to translate potential and vision into reality through commitment and perseverance spiced with some chutzpa.”

Dr. Efrat Shefer - IATI Board Member, President, Philips Israel

"The vibrant Israeli life science ecosystem provides unique opportunities. Close connections between academia, health providers, industry, health insurance, venture capitals and government combined with out-of-the-box ideas result in breakthrough innovation."

Elka Nir - IATI Board Member , CEO of Carmel ltd. and Carmel Innovations fund

“The strength of the Israeli life science industry lies in the unique combination of leading innovative technologies some of which are transformed from other successful Israeli fields. Including a strong ecosystem academy, hospitals, investors, large multinational companies and most importantly experienced entrepreneurs who are committed to advance game changing ideas in a very lean and cost-effective way."

Dr. Eran Eden - IATI Board member, Co-founder & CEO, MeMed

“The Israeli HealthTech industry benefits from a continuous influx of early stage life science innovation, generated by its leading academic and research institutes. Adding the Israeli cultural tolerance for risk taking and the healthy disregard of conventions into the mix, creates a fertile ground for early stage innovation and startups that have the potential to grow into meaningful sustainable companies.”

Dr. Frida Grynspan - Head of Lonza Collaborative Innovation center, Lonza Israel Ltd.

“The major strengths of the Israeli Life Science Industry lie in: Tight ecosystem of academic researchers, entrepreneurs, start-up companies, investors and multinational biotech and pharma companies that encourage cross talk and fruition of ideas; A growing drive of academic scientists to apply basic research and innovative solutions to industrial and commercial challenges, leading to translational research and technology transfer; Unique funding structures and collaborative frameworks, of the Israeli Innovation Authority, which encourage and promote high risk projects and out of the box solutions to industry challenges including in the manufacturing of complex biologics.”


Dr. Gidi Leshetz - CEO, Assuta Medical Centers Ltd.

"The strength of the life science industry in Israel lies in the talented people behind the technology, the early adoption of cutting edge methods and devices and the unique creativity of the human resource"

Gilad Glick - CEO, Itamar Medical

"The strength of the life science industry is based on few foundations. The first is the brilliant minds educated in the strong academic institutions in Israel while maintaining the entrepreneurial spirit and imagination known as “Start Up Nation”. The 2nd is the support provided by the Israeli Innovation Authority that makes it possible for those scientific founders to take reas onable business risk and pass the first stage of creating a new product. And the 3rd is the network of supporting functions such as regulatory and quality that is well developed based on years of success. That said, Israel is still lacking strength is sales and marketing functions which drive early stage companies to either sale early or struggle commercially."

Dr. Guy Ezekiel - Managing Director, Pitango HealthTech Fund

“Human capital is what makes the Israeli life science industry flourish. Researchers, engineers, clinicians and entrepreneurs – driven with a focused mission of changing the practice of medicine, creating groundbreaking inventions and companies.”

Guy Meger - CTO, VP R&D, Israel General Manager, EarlySense

"The strength of the life science industry in Israel lies in creativity, out of the box thinking and “we can do” approach. In addition, good communication between different disciplines that allows valuable information exchange between the care giver and the engineer.

When facing a challenging situation, the focus is more around finding solution than anything else, even when there is still high uncertainty and much to learn, taking in mind failure is an option, still, it is better than not trying.

Some of the acts done for example in the COVID-19 pandemic shows the innovative thinking and the high level of risk taking when deciding to use early stage technologies in medical setups to help controlling the crisis."

Dr. Itai Kela - Head of Healthtech and the Bio-Convergence national program, IIA

"Bio-Convergence has a transformative impact on healthcare, is a quantum leap in the world of drug development, industrializing drug discovery, making cell and gene therapy mainstream and enabling programming biology at scale"

Ittai Ben Zeev - CEO, TLV Stock Exchange

"The strength of the life science industry in Israel is built on groundbreaking ventures and developments that place it at the forefront of global technology in the development of new medicine, advanced medical devices, BI and more. In 2020, the Tel Aviv Stock Exchange introduced IPO's of R&D partnerships, including in the life sciences sector, in order to facilitate their continued development of growth through public funding. Lately, the Innovation Authority launched an investment track for institutional investors investing in Israeli high-tech companies, which provides a state guarantee of 40% for equity portfolios invested by institutional investors in Israeli high-tech companies.


Israel Makov - Chairman of SUN Pharmaceutical Industries Limited, Chairman of BioLight Life Sciences Ltd. and Chairman of Micromedic Technologies Ltd.

“The true potential of the Israeli life science industry lies in developing the competences needed to build start-ups into large and robust bio-pharma companies. These will become the industry pillars of sustainable growth and provide an ecosystem supporting the entire life cycle of innovation from bench to market.”

Itzik Goldwaser - President & CEO, Yissum

“The strength of Israel’s life science industry starts in the academia where our researchers rise to intellectual and real world challenges with critical creative thinking and rigorous world-class research. When the welfare of human society is faced with an unprecedented crises - such as we are currently experiencing - the researchers of Israel, with the full support of their academic institutions, are immediately able to translate the whole weight of their expertise and passion to develop actionable groundbreaking solutions. Hebrew University is at the forefront of this effort, bringing its industry leading research to advance the science of today and prepare us for the unknowns of tomorrow. “

Jonathan Berger - IATI Board Member, CEO, The Kitchen Food Tech Hub

“Biotechnology transforms the Food Industry in many ways, and Israel, being an oasis for biotechnologies ˆsuch as tissue engineering and gene editing, to name just a fewŠ, play significant roles in this trend.”

Jonathan Medved - IATI Board Member, CEO, Ourcrowd

"The strength of the life science industry in Israel is based on its world-class universities and research institutes where Nobel Laureates and acclaimed academics are conducting cutting-edge research and training the next generation of scientists. Israel’s unique multidisciplinary approach to the Life Science industry combines Artificial Intelligence, Sensors, big data and algorithms with deep clinical and medical insights to solve deep tech problems. The entrepreneurial vigor of Israel’s tech ecosystem now focused on Life Sciences is producing some of the world’s most innovative and far-sighted life science startups that will forever change the lives of billions."

Mati Gil - Senior Director, Teva Pharmaceutical Industries

“The strength of the Israeli life science industry lies in its highly skilled people; based on traditional academic excellence with added spirit of entrepreneurship, on innovative culture which encourages trial and error, on the way to sustainable innovative projects. These combinations encourage large bio-pharma companies grow and thrive

Miriam Shtilman Lavsovski - IATI Board Member, COO, Algotec Systems

“Israel’s flourishing life science industry enjoys a nourishing ecosystem of academic research and STEM education, teaching hospitals, a complementing software industry, supporting players such as multinational biotech companies as well as governmental support. The fact that this diverse ecosystem operates in a very packed geographical area provides more opportunities for cross industrycross discipline products and ideas."

This will strengthen the ties between Israeli high-tech and the Israel capital market, encouraging more R&D companies and partnerships to join TASE."


Dr. Miki Halberthal - General Director of Rambam Health Care Campus

"The strength of the life science industry in Israel lies in the Israeli informality way of thinking without artificial limitations and the philosophy that we have at Rambam Health Care Campus that involvement in research and innovation is part of our commitment and without it we will not be relevant. The life science industry goes hand in hand with clinical quality of care and has impact on the faculty achievements. The proximity and working within short circles is a big enhancement to creating meaningful products."

Nadav Kidron - IATI Board Member, CEO, Oramed Pharmaceuticals

“The strength of the Israeli life science Industry lies in our ability to rapidly bring concepts into the clinic with rapid turnaround times for prototypes. Our ability to constantly translate the amazing academic works done here in Israel into solutions for the whole world gives us the advantage as an industry.”

Ofer Gonen - CEO, Clal Biotechnology Industries

"The Israeli life sciences industry is unique in its ability to rapidly and effectively meet emerging challenges, such as the recent COVID-19 pandemic, by combining innovation and flexibility."

Ophir Shahaf - VP BD, eHealth Ventures

“As an early-stage investor in the digital health sector of the life science industry - we see that the year of the Corona has pushed digital health into the mainstream of modern medicine. As an incubator and investment fund focused exclusively on this space - we are experiencing a stellar deal flow and an increase in demand from our strategic partners. These are truly unprecedented times for the digital health sector.”

Dr. Osnat Luxemburg - Head of the medical technology, health information and research Directorate at the Ministry of Health

"The Israeli population benefits tremendously from the thriving life science ecosystem in Israel. We, in the Medical Technologies, Health Information and Research Directorate at the Ministry of Health, strive to improve regulation, promote innovation, and create a platform to connect all stakeholders in the ecosystem in order to generate a synergistic and holistic response to the ever-evolving technology. These efforts serve to make it possible for Israeli and multinational companies to sponsor groundbreaking technologies, grow and make their products available to those in need in a safe and effective manner and as rapidly and simply as possible. We are consistently working to realize the vast potential, which lies in the life science ecosystem in Israel."

Dr. Ron Sabar - Founder & CMO, Sabar Health

"The strength of the life science industry in Israel lies in the combination, of a plethora of brilliant minds working in all the relevant silos with the fact that, the Israeli life science eco system is still a small pond, where anyone can talk to anyone as if they were working on the same campus. This unique combination makes for fertile land where true bio convergence can flourish."


Prof. Ronni Gamzu - CEO, The Tel Aviv Sourasky Medical Center & Israel’s Former National Coronavirus Project Coordinator

"knowledge and scholarship and the dynamic spirit of innovation and entrepreneurship.All along conjoint with a startup ecosystem and proper public and private capital backbone. This is a propelling force for the Israeli economy, and we must continue to put efforts to flourish it further.”

Shlomo Mena - CPO Head & Country President Israel at Novartis

“Life sciences industry in Israel leans in its ability to create the next generation of therapy focus on cell and gene therapy.”

Dr Tal Patalon - MD, LL.B, MBA, head of KSM (Kahn-Sagol-Maccabi), Maccabi Research and Innovation Center

“Multi-omics research holds the key to the future of precision medicine. Incorporating genomic research with the vast data in longitudinal EMRs establishes Israel as a unique arena for fast, impactful medical advancements. The Israeli way of pushing the boundaries of what is possible, alongside our fierce protection of ethical standards is essential for this new and exciting era.”

Tal Levy - IATI Board Member, GM, BTG

“The strength of the life science industry in Israel lies in its amazing potential despite the fact that only a quarter of investments in Israeli Hi-tech is funneled to biotechnology, the branch provides approximately 40% of Hi-tech exports and approximately 10% of Israel’s total exports. Israel has accumulated several years of knowledge, expertise and experience, impressive academic abilities and can, no doubt, establish an active arena to attract more and more industrial companies. The sector is characterized by outstanding entrepreneurship and the impressive ability for invention of any scale, which manage to affect the lives and health of millions of people worldwide.”

Dr. Yair Schindel - IATI Board Member, Co-Founder & Managing Partner, aMoon Fund

“The convergence of Technology and Biology has engendering a global revolution in healthcare. If we work together; Innovators, Investors, Government, NGO’s, HMO’s and Academia, to leverage our digital strengths, I believe Israel will become one of the main global hubs of this HealthTech revolution. Building on our unique combination of topnotch. Physicians, Scientists and Tech Entrepreneurs we will contribute tremendously to the acceleration of cure globally. In tandem we will build a new and powerful economic growth engine for Israel.”

Prof. Yechezkel (Chezy) Barenholz - Head of Membrane and Liposome Research Lab, University Hadassah Medical School

“The advantages of the Israeli life science Industry lie in its strong qualities of innovation and entrepreneurship. But its biggest challenge is the lack the of knowledge and personnel needed for companies to ripen. This crucial shift involves turning from developing a prototype or reaching the start-up phase, to being a pharma / biomed company with strong abilities in regulation, patents and reimbursement. This traditional gap has to be closed in order for the Industry to grow up, and this can be done through business education of Israeli biomedical entrepreneurs.”


Prof. Yitshak Kreiss - Director General of Sheba Medical Center, Sheba Medical Center

"Israel possesses a community of top stakeholders such as the public healthcare system, elite academia, and of course a large number of innovative start-ups. Furthermore, it is other industries, and specifically the strong defense sector, which offers opportunities through bio-convergence."

Prof. Zeev Rotstein - CEO, Hadassah Medical centers

“The strength of the life science industry in Israel lies in its human assets. The industry is driven by highly talented, scientifically and academically oriented researchers, whose excellence and innovative thought processes attract equally talented business and industry visionaries. This symbiosis generates remarkable opportunities and achievements. It is therefore of great importance to encourage the nation’s youth to engage in higher education and for government to support higher education. The cerebral mass of all of the country’s researchers must be regarded as a national natural resource.”

Yaacov Michlin - IATI Co Chair (Life Science), CEO, BIOLIGHT Life Sciences Ltd.

“The excellent academic research in the biomed field in Israel, and its interplay with Israel’s entrepreneurial spirit and top tier engineering abilities, are a tremendous source of potential in this field in Israel. Over the years these factors have been supported by government policy. The combination of MNC R&D centers, with increased private support and investments from Israeli and foreign sources, will grow the biomed industry in a way that will enable companies to develop and flourish in Israel and generate a significant increase in employment opportunities in the field.”

Yaky Yanay - IATI Board Member, Co-CEO & President, Pluristem Therapeutics Inc

“The Israeli life science industry is about hope. A global hope for better wellbeing, quality of life and controlled healthcare spending. With the global aging phenomena, we need to find advanced ways to treat the sick and the elderly. The Israeli innovative approach and the out of the box thinking have a major role in converting the challenge into opportunity.”

Yaron Itzhari - Country Director, Medtronic

"The strength of the MeTtech industry in Israel lies in its ability to combine innovative medical needs from idea to execution in a unique healthcare environment AND boost the local economy, leading and setting tone for the global ecosystem"

Dr. Yael Gruenbaum - General Manager, Medison Ventures

"I strongly believe that the combination of a patient-centric approach and cutting-edge science are key to success in the life science industry. The Israeli life science industry already possesses this wining combination. As a result, it is in a promising position to offer breakthrough solutions. We must continue to support this ability by encouraging research and development in the industry and academia, as well as fueling innovation through investments in healthcare."


Yonatan Adiri - Founder & CEO, Healthy.io

“One of the strengths of the life science industry in Israel lies in the ecosystem’s understanding that the new deity in virtual white coat will not emerge. Instead of trying to build the “AI doctor god”, hailed as the new deity in a virtual white coat, Israeli entrepreneurs focus on a swarm of thoughtful and highly specific uses of AI in the healthcare space such as predictive ER management systems šClew›, specific radiological outputs, Zebra, Viz, AIDOC› and meaningful big-data correlations such as Coloscore to name a few.”

Yotam Drechsler, CEO BrainQ technologies

"The life science ecosystem is emerging into a healthtech ecosystem where bold visions are implemented by multidisciplinary approaches with lean and agile management. The startup nation DNA is gradually effecting this traditional industry and I believe we're going to see Israeli companies at the forefront of some of the emerging trends like AI-based diagnostics, remote care, computational biology etc."

Zeev Zehavi - Vice President, Venture Investments, Johnson & Johnson Innovation

“Israel is one of the largest providers of medical device solutions worldwide and has been able to maintain its leadership in life sciences because of a highly educated workforce and a culture that embraces and supports medical and technical ingenuity. JJDC repeatedly invests in Israel not only because of the transformative innovation coming out of companies established here, but also the collaborative business environment that enables partnerships to flourish.”

Zohar Gendler - Managing Partner & CEO, NGT VC

"The combination of solid infrastructure (networking, experienced managers, universities, engineering companies, top level employees, IP and regulatory experts, R&D centers) with high level of research and very talented entrepreneurs is the basis for the success of the Israeli life-science industry."


IATI - Israel Advanced Technology Industries89 Medinat HaYehudim St.,Bldg E, Herzliya Pituach, IsraelTel: +972 (0)73 713 [email protected], www.iati.co.il

iati israel’s life science annual industry report

Documents